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Abstract
Background To study the use of interferon-
gamma release assay (IFN-c) (IGRAs) as a
diagnostic test for tuberculosis (TB)-associated
uveitis (TAU).
Design Prospective cohort study.
Participants Consecutive new patients
(n¼162) with clinical ocular signs suggestive
of TAU, seen 41 year period at a single
tertiary center.
Methods All subjects underwent
investigations to rule out underlying disease,
including T-SPOT.TB and tuberculin skin test
(TST). Twenty-one subjects with underlying
disease and three with interdeterminate
T-SPOT.TB results were excluded. Those with
T-SPOT.TB- or TST-positive results were
referred to infectious diseases physician for
evaluation. Anti-TB therapy (ATT) was
prescribed if required. Patients’ treatment
response and recurrence were monitored for
six months after completion of ATT, if given;
or 1 year if no ATT was given.
Main outcome measure Diagnosis of TAU.
Results Mean age of study cohort (n¼138)
was 46.8±15.3 years. Majority were Chinese
(n¼80, 58.0%) and female (n¼75, 54.3%). TST
was more sensitive than T-SPOT.TB (72.0% vs
36.0%); but T-SPOT.TB was more speciﬁc
(75.0% vs 51.1%) for diagnosing TAU. Patients
with either a T-SPOT.TB (1.44; 95% conﬁdence
intervals (CI), 0.86–2.42) or TST (1.47; 95% CI,
1.12–1.94)-positive result are more likely to
have TAU. The accuracy of diagnosing TAU
increases when both tests are used in
combination (area under the receiver operator
curve¼0.665; 95% CI, 0.533–0.795). Patients
with both tests positive are 2.16 (95% CI,
1.23–3.80) times more likely to have TAU.
Negative T-SPOT.TB or TST results do not
exclude TAU (negative likelihood ratios o1.0).
Conclusions We recommend using a
combination of clinical signs, IGRA, and TST
to diagnose TAU.
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Introduction
The WHO (World Health Organization) in 2009
reported an increasing number of tuberculosis
(TB) infections in both the developing and
developed world due to multi-drug resistant
TB, HIV, and global migration.
1–3 It is estimated
that 70–80% of all TB infections in
immunocompetent individuals are latent.
1
Mycobacterium tuberculosis (MTB) can infect
the eye directly or cause inﬂammation by
antigenic mimicry, whereby the host produces a
cross-reactive immune response to an unseen
source of TB infection.
4–6 Unfortunately, tests
such as of MTB cultures, acid-fast bacilli (AFB)
smear, or PCR detection of MTB DNA from
ocular samples have low sensitivities (20–30%).
4
Both the immune-mediated mechanism of
inﬂammation as well as small inoculum of MTB
in the eye may account for this.
The incidence of TB in Singapore is about 40
per 100000 per year, compared with Western
Europe and the US (o25 per 100000) and high
burden countries such as India (4300 per
100000) F (Global tuberculosis control: a short
update to the 2009 report WHO/HTM/TB/
2009.426). Currently, the diagnosis and
treatment of TB still depend on the century-old
Mantoux test or tuberculin skin test (TST) F
which is still routinely performed on all patients
with uveitis in our clinical practice.
7 TST has a
low speciﬁcity due false-positive response in
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or vaccinated with BCG.
8,9 IGRAs such as T-SPOT.TB
(Oxford Immunotec, Oxford, UK) and QuantiFERON-TB
Gold In-tube or QFT (Cellestis Incorporated, Carnegie,
Australia) are more speciﬁc and sensitive than TST in
detecting active pulmonary TB infections.
10 However,
they are less sensitive for diagnosing latent TB infections
(LTBI).
11 In Singapore, T-SPOT.TB was found to be more
sensitive than QFT when both tests were evaluated for
diagnosing pulmonary TB.
12,13 However, T-SPOT.TB has
not been studied speciﬁcally for diagnosing tuberculosis-
associated uveitis (TAU). In this study, we compared
T-SPOT.TB with the TST as a diagnostic test for TAU.
Materials and methods
Study participants and overview of management
We conducted a prospective cohort study of all new
consecutive patients with uveitis presenting to the
Singapore National Eye Centre (SNEC) Ocular
Inﬂammation and Immunology Service 41 year period
(1 September 2008 to 31 August 2009). Ethics approval
was obtained from our local Institutional Review Board.
Patients were enrolled if they had clinical ocular signs
suspicious of TAU such as granulomatous inﬂammation,
broad-based posterior synechiae, retinal vasculitis with
or without choroiditis, and serpiginous-like choroiditis,
as deﬁned by Tabbara
21,41 and Gupta et al,
4,14 and
consented to participate in the study. All applicable
institutional and governmental regulations concerning
the ethical use of human volunteers/animals were
followed during this research.
Brieﬂy, all study subjects underwent a full systemic
review, ocular examination, and standard baseline
investigations F Figure 1. Blood was taken for
T-SPOT.TB before TST was performed. Patients were
excluded if they had (1) any other possible infectious or
non-infectious cause to account for the uveitis or (2) a
T-SPOT.TB result that was indeterminate as these tests
cannot be interpreted. All patients were referred to the
infectious diseases physician at Singapore General
Hospital for review and were prescribed Anti-TB therapy
(ATT) if required. Patients were followed up every 2
weeks for 8 weeks, then 2–3 monthly (or more frequently
as required) to monitor response to therapy. Systemic
corticosteroids were added if there was any increase in
ocular inﬂammation after commencing ATT,
15 deﬁned as
a two-step increase in inﬂammation using the
Standardization of Uveitis Nomenclature (SUN) working
group activity score.
16 Patients were followed up for a
period of 6 months after completion of therapy (if ATT
was given) or a minmum of 1 year if no ATT was given
(whichever was longer).
Investigations
All patients had standard baseline investigations such as
complete blood count, erythrocyte sedimentation rate,
liver enzyme panel, infectious disease screen (which
included Venereal Disease Research Laboratory (VDRL)
test for syphilis, TST, urine microscopy), and a chest
X ray (CXR). Other tests such as QFT, AFB smears from
throat swabs or PCR assays for TB DNA were performed
in patients with severe anterior chamber inﬂammation to
exclude TB.
T-SPOT.TB was performed according to the
manufacturer’s instructions, and blood was taken before
the TSTwas administered.
17 For each patient, 8ml of blood
was collected in Lithium Heparin tubes and processed
within 8h. Peripheral blood mononuclear cells (PBMCs)
were prepared by density gradient centrifugation over
Ficoll PaquePlus (GE Healthcare Bio-Sciences AB, Uppsala,
Sweden). A total of 250000 cells were seeded in each of
four wells of the assay plate. The cells were stimulated for
16–20h (under 5% carbon dioxide at 371C) with medium,
GIBCO AIM-V (Invitrogen Corporation, Carlsbad, CA,
USA) (nil control), phytohaemagglutinin (mitogen-positive
control), or the TB-speciﬁc peptide antigens (peptide
pools for early secretory antigenic target-6 (ESAT-6)
(Panel A) and for culture ﬁltrate protein-10 (CFP-10)
(Panel B), in separate wells) in a total volume of 150ml
History
Ocular & Sytemic Examination
Baseline investigations
T.SPOT.TB
TST/ T-SPOT.TB positive
(n = 93)
TST / T-SPOT.TB negative
(n = 45)
Follow-up interval
2-weekly for 8 weeks, then
2-to 3-monthly
Follow-up duration
6 months post-completion of
ATT 
OR
1 year from recruitment
(whichever is longer) 
Indeterminate T.SPOT.TB
(n = 3)
Other etiology  (n = 21)
Study Subjects
(n = 138) 
Tuberculin skin test (TST)
￿
￿
￿
￿
Figure 1 Flowchart depicting study cohort and follow-up.
n, number of study subjects; ATT, anti-tubercular treatment.
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Eyeper well. Two readers quantiﬁed the number of IFN-g
spot-forming T cells visually, and a third reader was
consulted if results were disparate.
TST was performed by using the standard Mantoux
method: intradermal injection of 0.1ml (two tuberculin
units (T.U.)) puriﬁed protein derivative (RT23 SSI F
2T.U./0.1ml Statens Serum Institut, Copenhagen,
Denmark). Induration was measured at 72hours with a
ruler and considered positive if it measured Z15mm
(as validated in our population).
9,18 A CXR with evidence
of pulmonary nodules, with or without visible
calciﬁcation and/or ﬁbrotic scars in the hilar area or
upper lobes was considered as a positive CXR ﬁnding.
7
Treatment and management of patients
The infectious diseases physician at the Singapore
General Hospital independently evaluated all patients
with a high clinical index of suspicion for TB, positive
TST or T-SPOT.TB. Those found to have associated
systemic or pulmonary TB infection received ATT,
whereas uveitis patients with LTBI were advised on
the risk–beneﬁt ratio of ATT.
19 Patients consenting to
treatment received standard ATT according to CDC
guidelines (isoniazid 5mg/kg daily, rifampicin
450–600mg daily, pyrazinamide 30mg/kg daily, and
ethambutol 15mg/kg daily for 2 months, followed by
two drugs for a 4-month continuation phase, for a total
minimum of 6 months duration).
19,20
In patients with posterior segment inﬂammation
where ATT was not indicated, oral prednisolone was
used at a starting dosage of 1mg/kg body weight,
tapering slowly over the clinical course was given. Any
anterior segment inﬂammation was treated with topical
corticosteroids. The therapeutic response was monitored
by one ophthalmologist (SPC), where a two-step decrease
in inﬂammation (SUN working group activity score) was
considered an improvement in clinical activity and a
positive response to treatment.
16
Deﬁntion of TAU
The ﬁnal diagnosis of TAU was only made at the end of
our study, after all patients had completed treatment and
follow-up. We adapted our criteria from published
deﬁnitions by Gupta et al
4 and Tabbara.
21 A deﬁnite
diagnosis of ocular TB infection was made in patients
with a positive AFB smear, MTB culture, or PCR assay
from ocular samples.
21 Patients without an underlying
disease who responded to corticosteroid therapy alone
and no ATT, with no recurrence within 1 year were
presumed not to have TAU. Patients with no deﬁnite
source of TB infection, who responded to ATT within
4–6 weeks of treatment without recurrence for 6 months
following completion of therapy, having had other
diseases excluded were presumed to have TAU.
4
Statistical analysis
We studied the ﬁnal diagnoses of all patients and
compared their TST or T-SPOT.TB results after 6 months
of completing therapy (Figure 2). We classiﬁed each
patient’s anatomical location, course, and laterality of
ocular inﬂammation according to the International
Uveitis Study Group clinical classiﬁcation criteria.
22
Statistical analysis included descriptive statistics, where
the mean and SD with 95% CI was calculated for the
continuous variables whereas frequency distribution and
T-SPOT.TB test (S) Tuberculin Skin Test (T)
T-SPOT.TB test (S) and Tuberculin Skin Test (T)
Study Cohort
(N=138)
TB uveitis:
Yes = 18 (45.0%)
No = 22 (55.0%)
TB uveitis:
Yes = 32 (32.7%)
No = 66 (67.3%) 
S+ (n=40) S- (n=98)
TB uveitis:
Yes = 14 (23.7%)
No = 45 (76.3%) 
T- (n=59)
Study Cohort
(N=138)
T+ (n=79)
TB uveitis:
Yes = 36 (45.6%)
No = 43 (54.4%) 
Study Cohort
(N=138)
TB uveitis:
Yes = 11 (42.3%)
No = 15 (57.7%) 
TB uveitis:
Yes = 7 (15.6%)
No = 38 (84.4%)
S+T+ (n=26) S-T- (n=45) S+ (n=14) T+ (n=53)
TB uveitis:
Yes = 7 (50.0%)
No = 7 (50.0%) 
TB uveitis:
Yes = 25 (47.2%)
No = 28 (52.8%) 
Figure 2 Final diagnoses of study cohort following T-SPOT.TB test (S), tuberculin skin test (T) and when used in combination (SþT).
þ, positive;  , negative.
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Eyepercentages were used for categorical variables. One-way
ANOVA was used to compare means of outcome groups
for each characteristic variable whereas Pearson’s square
w
2-tests (incorporating Yates’ correction if necessary)
were used to assess the independent association between
characteristic variables and outcome groups. A P-value
o0.05 was considered statistically signiﬁcant.
Performances of binary classiﬁcation tests were
evaluated using sensitivity, speciﬁcity, and area under
the receiver operator curve (AUC). All analyses were
performed using STATA version 11 (StataCorp LP,
College Station, TX, USA).
Results
A total of 162 consecutive, new patients with uveitis were
enrolled during our study period (Figure 1). After initial
assessment, we excluded 21 patients (13.0%) with
underlying diseases that confound the ﬁnal diagnosis of
TAU and three patients (1.9%) with indeterminate
T-SPOT.TB results (Figure 1). Patients excluded were
HLA-B27 positive (n¼10), VDRL positive (n¼5), or
those diagnosed with herpetic anterior uveitis (n¼4) and
sarcoidosis (n¼2). All three patients with indeterminate
T-SPOT.TB results had unilateral acute anterior uveitis
successfully treated with topical steroids, with no
recurrence of inﬂammation at the end of our study
period. All remaining 138 patients did not have an
infectious or non-infectious cause for ocular
inﬂammation detected by the end of their follow-up
period.
The clinical characteristics of the 138 study subjects are
seen in Table 1. The mean age of these patients was
46.8±15.3 years. The majority were Chinese (n¼80,
58.0%) and female (n¼75, 54.3%). We found no signiﬁcant
differences in terms of age, gender, race, or anatomical
classiﬁcation of uveitis between patients with positive or
negative T-SPOT.TB results. Patients presented with
ocular signs consistent with a tubercular cause such as
granulomatous (n¼10) or medium keratic precipitates
(n¼52); iris nodules (n¼16); broad and extensive
posterior synechiae (n¼36); choroiditis (n¼14),
serpinginous choroiditis, (n¼1) or vasculitis (n¼33).
There were no cases of deﬁnite ocular TB infection in this
study cohort as nine patients had vitreous biopsy and
were found to have no evidence of a positive AFB smear,
MTB culture, or PCR assay from these ocular samples.
However, ﬁve patients (3.7%) had AFB smear-positive
sputum samples and two (1.5%) patients had positive
PCR results from urine samples. The majority of patients
(124/138, 89.9%) had CXR ﬁndings that were not
suggestive of pulmonary TB infection, as deﬁned.
7 At o t a l
of 50 patients were presumed TAU as deﬁned in our
study, and completed ATT for a median duration of 6.9
(range 6–9) months. All patients who were treated with
ATT resolved with no recurrence. The remaining patients
(n¼88) were presumed negative and were responsive to
corticosteroid therapy only.
The study cohort was divided into four main groups,
as illustrated in Figure 2: SþTþ (both T-SPOT.TB and
TST positive), Tþ (only TST positive, T-SPOT.TB
negative), Sþ (only T-SPOT.TB positive, TST negative),
Table 1 Demographics and anatomical classiﬁcation of uveitis in study cohort
Characteristics All (n¼138) T-SPOT.TB result
Positive (n¼40) Negative (n¼98) P-value
a
Age, years (±SD) 46.8 (15.3) 46.9 (14.4) 47.7 (15.5) 0.74
Gender (%)
Male 63 (45.7) 23 (57.5) 28 (40.8)
0.09
Female 75 (54.3) 17 (42.5) 29 (59.2)
Race (%)
Chinese 80 (58.0) 21 (52.5) 59 (60.2)
Malay 12 (8.7) 1 (2.5) 11 (11.2)
Indian 27 (19.6) 13 (32.5) 14 (14.3) 0.09
Caucasian 2 (1.4) 0 (0.0) 2 (2.0)
Others 17 (12.3) 5 (12.5) 12 (12.3)
Type of Uveitis
b (%)
Anterior 66 (48.2) 21 (52.5) 45 (46.4)
Intermediate 14 (10.2) 1 (2.5) 13 (13.4) 0.34
Posterior 31 (22.6) 11 (27.5) 20 (20.6)
Panuveitis 26 (19.0) 7 (17.5) 19 (19.6)
aP-value from one-way ANOVA or w
2-test as appropriate.
bAnatomical classiﬁcation according to the Standardized Uveitis Nomenclature (SUN) Working group.
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Eyeand S T  (neither test positive). The statistical basis of
our study involves the comparison of these four groups
and their respective ﬁnal diagnosis of TAU. We estimated
the sensitivities, speciﬁcities, and AUC of each test
individually and when used in combination (Table 2).
In the analysis of each test individually, the TST (60.9%;
95% CI, 52.7–69.0) has a higher diagnostic accuracy than
the T-SPOT.TB (58.7%; 95% CI, 50.5–66.9). Although the
TST is more sensitive as compared with T-SPOT.TB
(72.0% vs 36.0%), the latter is more speciﬁc for diagnosis
(75.0 vs 51.1%). The incorporated ROC (AUC) value for
TST (0.616; 95% CI, 0.534–0.698) was greater than for
T-SPOT.TB (0.555; 95% CI, 0.474–0.636) F Figure 3.
When both T-SPOT.TB and TST are used in
combination, the overall accuracy for predicting TAU
increases to 69.0% (95% CI, 57.5–78.6%) with a higher
AUC of 0.665 (95% CI, 0.533–0.795) F Figure 4. If both
tests are positive (SþTþ), the positive likelihood ratio is
2.16 (95% CI, 1.23–3.80). In patients with both tests
negative, 82.2% (37/45) patients resolved with no
recurrence despite treatment without ATT. However, the
negative likelihood ratio was o1.0 for patients with both
tests negative (0.54; 95% CI, 0.30–0.99). The concordance
of both tests was low (k-value¼0.085 (P¼0.239)) in our
study cohort. Discordant results were found in 67/138
(48.6%) cases. In these patients, the positive likelihood
ratios were comparable in patients with SþT  (1.44;
95% CI, 0.86–2.42) and S Tþ (1.47; 95% CI, 1.12–1.94);
whereas the negative likelihood ratios were o1.0 for
patients with SþT  (0.85; 95% CI, 0.67–1.09) and S Tþ
(0.54; 95% CI, 0.34–0.89). No signiﬁcant risk factors were
identiﬁed for discordant results such as age (P¼0.38),
gender (P¼0.73), race (P¼0.33), or type of uveitis
(P¼0.54). We used the observed prevalence of TAU to
compare the prior probability of disease with the positive
and negative predictive values (PPV and NPV,
respectively). Although T-SPOT.TB and TST each had a
greater PPV (45.0% and 45.6%, respectively vs the prior
probability of 36.2% F an improvement of 9%),
combining the test results improved the PPV over the
prior probability by 17%.
Discussion
Our study found that patients with suggestive clinical
signs of TB plus either a positive TST or T-SPOT.TB were
Table 2 Comparison of accuracy between T-SPOT.TB (S), Tuberculin skin test (T), and combination (SþT)
Features of diagnostic tests Diagnostic tests, (95%CI)
ST S þT
Sensitivity 36.0% (24.1, 49.9) 72.0% (58.3, 82.5) 61.1% (38.6, 79.7)
Speciﬁcity 75.0% (65.0, 82.9) 51.1% (40.9, 61.3) 71.7 (58.4, 82.0)
Positive predictive value 45.0% (30.7, 60.2) 45.6% (35.1, 56.5) 42.3% (25.5, 61.1)
Negative predictive value 67.4% (57.6, 75.8) 76.3% (64.0, 85.3) 84.4% (71.2, 92.3)
Positive likelihood ratio 1.44 (0.86, 2.42) 1.47 (1.12, 1.94) 2.16 (1.23, 3.80)
Negative likelihood ratio 0.85 (0.67, 1.09) 0.54 (0.34, 0.89) 0.54 (0.30, 0.99)
Accuracy 60.9% (52.7, 69.0) 58.7% (50.5, 66.9) 69.0% (57.5, 78.6)
AUC 0.555 (0.474, 0.636) 0.616 (0.534, 0.698) 0.665 (0.533, 0.795)
Abbreviations: CI, conﬁdence intervals; AUC, area under the receiver operator characteristic curve; S, T-SPOT.TB; T, Tuberculin skin test.
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0.50
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Figure 3 AUC for tuberculin skin test (T) and T-SPOT.TB (S).
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Area under ROC curve = 0.6640
Figure 4 AUC combining tuberculin skin test (T) and
T-SPOT.TB (S).
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Eyeapproximately 1.5 times more likely to have TAU as
compared with patients with negative tests. We also
found that T-SPOT.TB is more speciﬁc but less sensitive
than TST, and when both tests are used in combination
the overall accuracy for diagnosing TAU increases.
Patients with suggestive clinical signs in addition to
positive TST and T-SPOT.TB have a two times increased
likelihood of having TAU. On the other hand, we found
that both tests (used individually or in combination)
have poor sensitivities. Therefore, neither a negative
T-SPOT.TB nor a negative TSTresult, in patients who have
ocular signs suggestive of a tubercular cause, adequately
excludes TAU (negative likelihood ratios o1.0 for both
tests individually and in combination F Table 2).
In our clinical practice, a high index of suspicion is
required to diagnose TAU. Current clinical practice
involves diagnosing TAU by using a positive TST and
suggestive clinical signs such as broad-based posterior
synechiae, retinal vasculitis with or without choroiditis,
and serpiginous-like choroiditis.
14 Our study found that
adding T-SPOT.TB increases the discrimination and
accuracy of diagnosing TAU. However, it must be noted
that the AUC value of combining T-SPOT.TB and TST
with clinical signs is only fairly good for discrimination
(AUC¼0.665). Our ﬁndings are consistent with
published studies, which found low sensitivities for
T-SPOT.TB and TST in patients with extrapulmonary
and latent TB.
23 This makes negative T-SPOT.TB or TST
results difﬁcult to interpret, as up to 20% of persons
with negative tests may still have TB infection.
24,25
However, the results of our study should be taken in
consideration together with the prevalence of disease
and the prior probability of disease. In the same study
period, we diagnosed TAU in 50 out of 621 patients with
uveitis (8%), which is consistent with our intermediate
burden of TB disease. The estimated prevalence of
tubercular uveitis range from 1–4% areas with low TB
endemicity such as USA, Europe, and Japan to 10–26%
in highly endemic regions such as India and Saudi
Arabia.
26–28
T-SPOT.TB is an objective, reproducible blood test that
requires only one visit to detect TB infection.
11 It is more
speciﬁc as it uses two MTB proteins, ESAT-6, and CFP-10
to stimulate IFN-g response from circulating CD4
T-cells.
17 The main disadvantage of T-SPOT.TB is its
higher cost and the need for trained personnel. Moreover,
the handling and transport of blood samples T-SPOT.TB
is both time and temperature sensitive. Thus, for it to be
cost-effective, T-SPOT.TB was recommended only in
those with a positive TST result.
29 Our study found that
the agreement between the TSTand T-SPOT.TB to be low
but unlike other studies did not ﬁnd any signiﬁcant
contributory factors for discordant results such as age,
gender, or race.
30,31
We recommend that both tests be performed
simultaneously and interpreted with clinical signs, as
T-SPOT.TB complements TST to improve the accuracy
of diagnosing TAU. This is consistent with our previous
recommendation of using QFT and TST.
32 T-SPOT.TB
differs from QFT in that the former involves harvesting
and counting viable PMBCs that release IFN-g whereas
the latter uses an enzyme-linked immunosorbent assay
to study IFN-g release from T-cells in whole blood. The
technique used in T-SPOT.TB may have better resolution
of blood samples with reduced T-cell numbers (for
example, samples from immunocompromised
individuals) that would usually give indeterminate
QFT results.
11
Recent efforts by WHO to stop the spread of TB
underline the need for early and accurate diagnosis of
TB.
33 TAU is often diagnosed late and under-treated.
34
ATT has been shown to reduce recurrence in patients
with TAU.
35 However, owing to the long course of
multiple medications and their potential side effects,
clinicians and patients alike are averse to ATT. TST is
highly subjective, non-speciﬁc for MTB, and may be
affected by the patient’s immune system.
36 This
reinforces our recommendation to perform both
T-SPOT.TB and TST to guide treatment decisions.
The main limitation of all studies involving
extrapulmonary TB including TAU is the limited number
of patients who have a positive TB culture, which is
the gold standard for diagnosis.
11,32,37,38 We used a
recognized deﬁnition of TAU in our study that was used
in many other studies and indeed, in our clinical
practice.
4,21,32,34,35,39–41 Our study is also limited by the
relatively small sample size, but to our knowledge, is the
largest prospective study on T-SPOT.TB used speciﬁcally
for the diagnosis of TAU. Currently, logistical and
cost-related issues restrict the use of T-SPOT.TB in our
daily clinical practice.
In conclusion, we found that although T-SPOT.TB is more
speciﬁc for TAU, it serves as a better diagnostic tool if used
in conjunction with the TST. Therefore, we recommend that
T-SPOT.TB be used as an adjunctive tool to be used with
clinical signs and TST in the diagnosis of TAU.
Summary
What was known before
K T-SPOT.TB is a useful diagnostic test for pulmonary
tuberculosis infections. T-SPOT.TB may not be as useful
for diagnosing tuberculosis-associated uveitis.
What this study adds
K T-SPOT.TB is a useful adjunct to diagnosing tuberculosis-
associated uveitis. T-SPOT.TB adds discrimination (using
area under the receiver operator curve) when used
together with clinical signs, suggestive of tuberculosis and
Mantoux.
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